ARCTURUS THERAPEUTICS HOLDINGS INC. Other Noncash Income (Expense)
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Other Noncash Income (Expense) of -$502.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for the quarter ending 2023-09-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for the quarter ending 2023-06-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for the quarter ending 2023-03-31 was -$502.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for fiscal 2023 was -$502.00K.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for fiscal 2022 was -$2.17M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for fiscal 2021 was -$1.99M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. other noncash income (expense) for fiscal 2020 was -$162.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | -$502.00K 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$502.00K 10-Q · filed 2024-11-07 | $2.41M derived: sum of 4 quarters · filed 2025-03-06 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$502.00K 10-Q · filed 2024-08-05 | $2.41M derived: sum of 3 quarters · filed 2025-03-06 | -$1.59M derived: sum of 4 quarters · filed 2025-03-06 | ||||
| 2023-03-31 | -$502.00K 10-Q · filed 2024-05-08 | $2.41M derived: sum of 2 quarters · filed 2025-03-06 | -$1.59M derived: sum of 3 quarters · filed 2025-03-06 | -$2.13M derived: sum of 4 quarters · filed 2025-03-06 | ||||
| 2022-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$1.09M derived: sum of 2 quarters · filed 2025-03-06 | -$1.63M derived: sum of 3 quarters · filed 2025-03-06 | -$2.17M 10-K · filed 2025-03-06 | ||||
| 2022-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$4.54M derived: sum of 2 quarters · filed 2023-11-14 | -$5.08M 10-Q · filed 2023-11-14 | -$3.90M 10-Q · filed 2022-11-09 | -$4.60M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | -$536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.08M 10-Q · filed 2023-08-07 | -$2.41M 10-Q · filed 2022-08-09 | -$595.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.49M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$546.00K 10-Q · filed 2023-05-09 | -$919.00K 10-Q · filed 2022-05-09 | -$59.00K derived: sum of 2 quarters · filed 2024-03-14 | -$953.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.84M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $487.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$407.00K derived: sum of 2 quarters · filed 2024-03-14 | -$1.29M derived: sum of 3 quarters · filed 2024-03-14 | -$1.99M 10-K · filed 2024-03-14 | -$3.38M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | -$894.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.78M derived: sum of 2 quarters · filed 2022-11-09 | -$2.48M 10-Q · filed 2022-11-09 | -$1.61M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$887.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.58M 10-Q · filed 2022-08-09 | -$718.00K derived: sum of 3 quarters · filed 2022-08-09 | -$1.09M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$696.00K 10-Q · filed 2022-05-09 | $169.00K derived: sum of 2 quarters · filed 2022-05-09 | -$204.00K derived: sum of 3 quarters · filed 2022-05-09 | -$584.00K derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $865.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $492.00K derived: sum of 2 quarters · filed 2022-03-01 | $112.00K derived: sum of 3 quarters · filed 2022-03-01 | -$162.00K 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | -$373.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$753.00K derived: sum of 2 quarters · filed 2021-11-09 | -$1.03M 10-Q · filed 2021-11-09 | |||||
| 2020-06-30 | -$380.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$654.00K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | -$274.00K 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | -$873.00K 10-K · filed 2022-03-01 | |||||||
| 2019-03-31 | -$212.00K 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | -$38.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |